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Episodic ataxia type 1 (EA1) is a K+ channelopathy characterized by a broad spectrum
of symptoms. Generally, patients may experience constant myokymia and dramatic
episodes of spastic contractions of the skeletal muscles of the head, arms, and legs with
loss of both motor coordination and balance. During attacks additional symptoms may
be reported such as vertigo, blurred vision, diplopia, nausea, headache, diaphoresis,
clumsiness, stiffening of the body, dysarthric speech, and difficulty in breathing. These
episodes may be precipitated by anxiety, emotional stress, fatigue, startle response or
sudden postural changes. Epilepsy is overrepresented in EA1. The disease is inherited
in an autosomal dominant manner, and genetic analysis of several families has led to
the discovery of a number of point mutations in the voltage-dependent K+ channel gene
KCNA1 (Kv1.1), on chromosome 12p13. To date KCNA1 is the only gene known to be
associated with EA1. Functional studies have shown that these mutations impair Kv1.1
channel function with variable effects on channel assembly, trafficking and biophysics.
Despite the solid evidence obtained on the molecular mechanisms underlying EA1,
how these cause dysfunctions within the central and peripheral nervous systems
circuitries remains elusive. This review summarizes the main breakthrough findings in
EA1, discusses the neurophysiological mechanisms underlying the disease, current
therapies, future challenges and opens a window onto the role of Kv1.1 channels in
central nervous system (CNS) and peripheral nervous system (PNS) functions.
Keywords: episodic ataxia type 1, KCNA1, Kv1.1 potassium channel, point mutations, channelopathy, episodic
ataxia type 1 therapy
Introduction
Encoded by more than 70 genes, K+ channels make up the largest group of ion
channels found in virtually all cells of the human body. A substantial number of diseases
known as channelopathies, described in both humans and animals, result from either
mutations or dysfunctions in K+ channels. Episodic ataxia type 1 (EA1) is one of the
first K+ channelopathies that was identified and included in a continuously growing list
Abbreviations: ACTZ, Acetazolamide; α-DTX, Alfa Dendrotoxin; CBZ, Carbamazepine; CNS, Central Nervous
System; EA1, Episodic Ataxia type 1; EA2, Episodic Ataxia type 2; EEG, Electroencephalography; EMG,
Electromyography; GABA, Gamma-Aminobutyric Acid; IPSCs, Inhibitory Post-Synaptic Currents; MRI, Magnetic
Resonance Imaging; PNS, Periferal Nervous System; WES, Whole-exome sequencing.
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(Adelman et al., 1995; Sicca et al., 2011; D’Adamo et al.,
2013; Ambrosini et al., 2014; Guglielmi et al., 2015; Parolin
Schnekenberg et al., 2015). In this report, we will review
ours and others past work and achievements, and retrace the
challenges encountered in pinning down the molecular and
neurophysiological mechanisms underlying this neurological
disorder. This undertaking will provide a comprehensive and
up to date account of our present understanding of EA1, and
indicate new directions for future studies.
Clinical Findings
Episodic ataxia type 1 [EA1; OMIM 160120] is a neuromuscular
disease described precisely by VanDyke et al. (1975). It is
characterized by constant myokymia (fine twitching of groups
of muscles, intermittent cramps and stiffness) and dramatic
episodes of ataxia accompanied by spastic contractions of
the skeletal muscles of the head, arms, and legs. In several
cases patients show loss of motor coordination and balance.
Attacks can last seconds or minutes, but in some cases many
hours (Lee et al., 2004). Recently, episodes characterized by
ataxia/dysarthria with concurrent hyperthermia (up to 40.3◦C)
that lasted for days were witnessed in-hospital (D’Adamo et al.,
2015). The frequency of attacks is variable. Some patients
present ataxia more than 15 times a day, while others less
than once a month (VanDyke et al., 1975). Generally the
onset of the disease is during childhood and can be triggered
by traumatic physical or emotional events (Imbrici et al.,
2008), as well as by stimuli like fever, startle response, abrupt
movements, vestibular caloric stimulation, anxiety, repeat knee
bends, exercise, ingestion of caffeine, and riding a merry-go-
round. High temperatures may also precipitate attacks (Eunson
et al., 2000).
Myokymia manifests during and between attacks, rarely
in the absence of ataxia or other neurological deficits. In
some EA1 patients myokymic activity is either absent on the
electromyography (EMG; D’Adamo et al., 2015) or becomes
apparent after the application of regional ischemia. Brunt and
vanWeerden (1990) proposed that the abnormal EMG responses
originated peripherally. A recent study in patients harboring EA1
mutations reported alterations in axonal excitability parameters
and proposed simple EMG protocols helpful to diagnose EA1
(Tomlinson et al., 2010).
Epilepsy is over-represented in EA1. Some affected patients
can present tonic-clonic and partial seizures (Imbrici et al., 2008)
and/or abnormal electroencephalograms (EEGs; VanDyke et al.,
1975; Zuberi et al., 1999; Lee et al., 2004).
Since the first description of EA1, the phenotypic spectrum of
the disease has widened considerably. Some affected individuals
may also display: delayed motor development, choreoathetosis,
carpal spasm, clenching of the fists, cognitive dysfunctions,
expressive language delay and inability to learn a motor
task (e.g., ride a bicycle; Zuberi et al., 1999; Demos et al.,
2009). A short sleep phenotype has been recently reported
(D’Adamo et al., 2015). Moderate muscle hypertrophy with
generalized increase inmuscle tone and bilateral calf hypertrophy
was observed in some individuals. Others display apnoea,
cyanosis, attacks of breathing difficulty (Zuberi et al., 1999;
Shook et al., 2008), and skeletal deformities (Kinali et al.,
2004; Klein et al., 2004). The magnetic resonance imaging
(MRI) neuroimage is usually normal, albeit a family with
cerebellar atrophy has been reported (Demos et al., 2009;
Glaudemans et al., 2009). It must also be pointed out that
phenotypic differences exist not only between families harboring
different mutations, but also between individuals of the same
family.
Genetics
EA1 is an autosomal dominant disorder involving heterozygous
point mutations in the gene KCNA1 on chromosome 12p13
which encodes for the voltage dependent K+ channel Kv1.1
(Figure 1; Browne et al., 1994, 1995; Litt et al., 1994; Comu
et al., 1996; Imbrici et al., 2008). To date KCNA1 is the only
gene known to be associated with EA1. Since several individuals
displaying typical EA1 symptoms do not carry variations in
KCNA1, it is highly likely that defects in other genesmay underlie
the disease. In patients with a complex phenotypic presentation
of EA1, the whole-exome sequencing (WES) can be a useful,
time-saving, and cost-effective diagnostic tool (Tacik et al., 2015).
Most individuals diagnosed with EA1 have an affected
parent, although de novo mutations have been identified
(Demos et al., 2009; Lassche et al., 2014). Despite the
identification of some nonsense and small deletion mutations,
the variations in the genetic code responsible for EA1 are
mainly missense point mutations (Figure 1; Eunson et al.,
2000; Shook et al., 2008). The majority of individuals carrying
a KCNA1 variant express the EA1 phenotype. However, not
all individuals with mutations phenotypically express EA1
making the penetrance of the disease incomplete. EA1 has a
disease prevalence of approximately 1:500,000, albeit it may
be an underestimation due to misdiagnosis or unreported
cases.
FIGURE 1 | KCNA1 mutations identified in episodic ataxia type 1 (EA1)
individuals. Cartoon showing the membrane topology of a human Kv1.1
subunit and the positions of the EA1 mutations. Up-dated and adapted from
D’Adamo (2010).
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The amino acid residues mutated in the Kv1.1 channel
of EA1 patients are located at positions highly conserved
throughout evolution, from Drosophila melanogaster to humans
(Browne et al., 1994). Interestingly, four different mutations
of the highly conserved threonine 226 located within the
second transmembrane segment were discovered (Figure 1;
Rajakulendran et al., 2007). Diverse phenotypic characteristics
may result from virtually identical channel defects arising from
similar mutations. For example epilepsy, infantile contractures,
postural abnormalities, and skeletal deformities are expressed
with the mutation p.Thr226Arg and not by p.Thr226Ala and
p.Thr226Met mutations. Vast differences in the severity and
frequency of attacks are observed even when the same EA1
mutation exists, as in identical twins (Graves et al., 2010).
Indeed, while one twin sought treatment the other who was
less severely affected did not require medication, suggesting
that the symptom heterogeneity can also be attributed to a
non-genetic factors (Graves et al., 2010; D’Adamo et al., 2015).
Due to such a wide interfamilial and intrafamilial phenotypic
variability genotype-phenotype correlations have been extremely
difficult to establish (Kullmann, 2010). Nevertheless, recently
some correlation attempts have been made (Graves et al., 2014).
Molecular Pathogenesis
The functionality and characteristics of several mutant channels
have been established by expression of the mutant gene in
Xenopus oocytes and mammalian cell lines, thereby determining
the molecular mechanisms underlying the EA1 mutations
(Table 1; Adelman et al., 1995; D’Adamo et al., 1998, 1999; Zerr
et al., 1998; Zuberi et al., 1999; Eunson et al., 2000; Manganas
et al., 2001; Imbrici et al., 2003, 2006, 2007, 2008, 2009; Cusimano
et al., 2004).
By studying the properties of Kv1.1 channels bearing the
EA1 point mutations, Adelman et al. (1995) first demonstrated
that the mutant channels showed altered gating properties.
In particular, they showed that V408A channels had faster
activation-deactivation kinetics and C-type inactivation, while
F184C channels displayed a 20 mV positive shift in voltage-
dependence.
TABLE 1 | Summary of the main functional defects caused by EA1 mutations.
Mutation Main functional defects compared to wild-type channels Reference
R167M Not functional with dominant negative effect Tomlinson et al. (2013)
V174F Marked reduction of surface expression Adelman et al. (1995)
I177N Reduction of surface expression with dominant negative effect, positive shift of voltage dependence of activation, slower
activation, faster deactivation
Imbrici et al. (2003)
F184C Reduction of surface expression, positive shift of voltage dependence of activation, slower kinetic of activation Adelman et al. (1995)
C185W Not functional with dominant negative effect Tomlinson et al. (2013)
D’Adamo et al. (2015)
T226A/M Marked reduction of surface expression, positive shift of voltage dependence of activation, slower deactivation, slower
activation
Zerr et al. (1998)
T226R Marked reduction of surface expression with dominant negative effect, positive shift of voltage dependence of activation,
slower activation, slower deactivation
Zuberi et al. (1999)
T226K Not functional with dominant negative effect Chen et al. (2007)
R239S Not functional with strong dominant negative effect Adelman et al. (1995)
A242P Marked reduction of surface expression, negative shift of voltage dependence of activation, slower activation, slower
deactivation
Eunson et al. (2000)
P244H No differences between wild-type and mutant Eunson et al. (2000)
F249I Marked reduction of surface expression, slower deactivation Adelman et al. (1995)
∆F250 N/A Shook et al. (2008)
N255D Not functional with dominant negative effect Glaudemans et al. (2009)
I262M Not functional with dominant negative effect Lassche et al. (2014)
I262T N/A Klein et al. (2004)
V299I Positive shift of voltage dependence of activation with dominant negative effect Rajakulendran et al. (2009)
L305F Dominant negative effect on the Kv1.1 potassium channel gating properties Poujois et al. (2006)
R307C Not functional with dominant negative effect, positive shift of voltage dependence of activation Graves et al. (2010)
G311S Reduction of surface expression, positive shift of voltage dependence of activation, faster C-type inactivation Zerr et al. (1998)
E325D Marked reduction of surface expression with strong dominant negative effect, 60mV positive shift of voltage dependence
of activation, faster deactivation, faster activation, faster C-type inactivation
Adelman et al. (1995)
L329I N/A Knight et al. (2000)
S342I N/A Lee et al. (2004)
V404I Small effect on surface expression, positive shift of voltage dependence of activation, slower activation, slower
deactivation
Eunson et al. (2000)
I407M Not functional with dominant negative effect Tomlinson et al. (2013)
V408A Faster activation and deactivation, faster C-type inactivation, faster recovery from inactivation Adelman et al. (1995)
V408L Faster C-type inactivation Demos et al. (2009)
F414C Not functional Imbrici et al. (2008)
F414S Not functional with dominant negative effect, positive shift of voltage dependence of activation Graves et al. (2010)
R417stop Not functional with dominant negative effect Eunson et al. (2000)
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A heterozygote for a KCNA1 mutation may or may not
express the normal and mutant allele equally. The extent of
functional impairment of a Kv1.1 channel is dependent on
the type and number of mutated subunits that make up the
tetrameric channel. As such, channels composed of two Kv1.1
wild-type and two mutated subunits present whole-cell and
single channel properties intermediate between tetramers made
up of four wild-type or four mutated subunits (D’Adamo
et al., 1998). Co-expression of wild-type and mutant subunits
for some EA1 mutations presented a dominant negative effect
resulting in less than half the normal current, while for other
mutations virtually no effect was observed (Zerr et al., 1998;
D’Adamo et al., 1999, 2015; Rea et al., 2002; Imbrici et al., 2006,
2011; Graves et al., 2010). Overall, these studies demonstrated
that allelic variations underlying EA1 exert variable loss-of-
function effects on the outward K+ flux through the channel
made-up of Kv1.1 subunits by altering channel expression
and gating. However, in the nervous system Kv1.1, Kv1.2
and Kv1.4 subunits are the most amply expressed, and they
often form heteromeric channels composed of Kv1.1/Kv1.2
and Kv1.1/Kv1.4 subunits. The question arose as to whether
or not EA1 mutations could alter the properties of these
channel types. In a seminal study, we were the first to
demonstrate the co-assembly of human Kv1.2 and Kv1.1
subunits to form a novel channel with distinct gating properties
markedly altered by EA1 mutations (D’Adamo et al., 1999). The
deleterious effects of EA1 mutations on heteromeric channel
function was also shown for Kv1.4–1.1/Kvβ1.1, a channel
highly expressed in the hippocampus (Imbrici et al., 2006).
Kv1.4 subunits confer fast N-type inactivation properties to
Kv1.4–1.1 channels. Intriguingly, EA1 mutations which have
normal surface expression reduce the rate of inactivation
conferred by Kv1.4 by decreasing the affinity for the inactivation
domain, while mutations which have reduced subunit surface
expression increase the rate of N-type inactivation. The latter
is due to a stoichiometric increase in the number of Kv1.4
subunits assembled in the tetramer (Imbrici et al., 2011).
Thus, subunit surface expression may inversely affect distinct
functional properties of the channel. In conclusion, these
studies have clearly demonstrated that allelic variations in a
single gene (KCNA1) also alter the function of other proteins
that interact with Kv1.1. These mechanisms are expected to
broaden the spectrum of the molecular defects caused by EA1
mutations.
Zn2+ ions that are released into the synaptic cleft
modulate the activity of distinct members of ligand-
gated and voltage-gated ion channels. Indeed, we have
shown that channels composed of Kv1.1/Kv1.4/Kvβ1.1
subunits possesses both a high affinity (<10 µM) and a
low affinity (<0.5 mM) site for Zn2+ ions. The intrinsic
affinity of these channels for Zn2+ binding was shown to be
enhanced by an EA1 mutation (e.g., F184C; Imbrici et al.,
2007).
The precise contribution of Kv1.1 defects described here on
signaling dysfunction, in the neural networks expressing this
channel, is not clear. We will address this issue in the next
paragraph.
Neurophysiological Pathogenesis
The expression pattern of Kv1.1 channels within the CNS
and PNS varies. Dysfunctions of circuits located in the
cerebellum, hippocampus, cortex and PNS have been implicated
in EA1. Here, we will attempt to correlate the anatomical and
subcellular location of Kv1.1 channels with their physiological
roles, molecular defects caused by EA1 mutations and clinical
findings.
Cerebellum
The cerebellum, known to play a crucial role in motor control
and cognitive function, is implicated in EA1. In fact, EA1
is characterized by typical symptoms of cerebellar pathology.
Kv1.1-containing channels show a discrete pattern of subcellular
localization in the cerebellum. In particular, Kv1.1 and Kv1.2
are extensively expressed at Pinceau synapses formed between
basket cell terminals and the initial segments of the Purkinje
cell axons, and at the juxtaparanodal regions of virtually all the
myelinated axons of the cerebellar white matter (McNamara
et al., 1993; Wang et al., 1993, 1994; Laube et al., 1996; Rhodes
et al., 1997). By contrast, Punkinje cells does not express Kv1.1
subunits (Khavandgar et al., 2005; Lorincz and Nusser, 2008).
In accordance with a prevalent expression of Kv1.1 subunits in
basket cell terminals, the amplitude and frequency of inhibitory
post-synaptic currents (IPSCs) in Purkinje cells, mediated by
type A gamma-aminobutyric acid (GABAA) receptor activation,
are increased by in vitro application of alfa dendrotoxin (α-
DTX), a selective blocker of Kv1.1 and Kv1.2 channels (Southan
and Robertson, 1998). We have previously proposed a model
in which a reduction of delayed rectifier current passing
through heteromeric channels composed of EA1Kv1.2 andKv1.1
mutated subunits increases excitability of presynaptic basket
cell terminals, prolongs action potential duration and enhances
Ca2+ ion influx. Larger amounts of GABA were predicted
to be released from basket cell terminals which could inhibit
action potential generation at the Purkinje axon hillock. As a
consequence, the inhibitory output of the entire cerebellum to
the rest of the brain could be markedly reduced, producing
the disinhibition of deep cerebellar nuclei and cerebellar
symptoms typically observed in EA1 patients (D’Adamo et al.,
1999). By inserting the heterozygous p.Val408Ala mutation in
one Kv1.1 allele a mouse model of EA1 that recapitulated
the disease was generated. In particular, a procedure that
mimics stress-fear responses induced motor dysfunctions in
Kv1.1V408A/+ animals similar to EA1 (Herson et al., 2003).
The p.Val408Ala is a homozygous lethal mutation that causes
embryonic death between E3-E9. Conversely, heterozygous
Kv1.1V408A/+ animals are viable. Electrophysiological recordings
from cerebellar slices dissected from Kv1.1V408A/+ animals
showed an increase in frequency and amplitude of spontaneous
GABAA IPSCs at cerebellar basket cell–Purkinje cell synapses
compared to wild-type Kv1.1+/+ mice (Herson et al., 2003).
The results of this study is in agreement with our postulated
pathogenetic model of EA1 (D’Adamo et al., 1999). A more
recent study provided further evidence supporting this model,
namely basket cell terminals of Kv1.1V408A/+ animals had
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broader action potentials at half amplitude than in wild-type
(Begum and Kullmann, 2011). Nevertheless, many questions
concerning the abnormalities within cerebellar circuitries that
underlie EA1 remain to be addressed. A basket cell axon
forms branches which make synaptic contact with several
Purkinje cells. Since Kv1.1 are highly concentrated at axonal
branch points (Tsaur et al., 1992; Wang et al., 1994), this
channel type may control the success rate of action potential
propagation down the axon. Direct evidence showing how EA1
mutations alter this important process has not been provided
to date. In addition, what determines the episodic nature of
the cerebellar symptoms is unknown. A phenomenon akin
to spreading acidification of the cerebellar cortex has been
suggested (Chen et al., 1999, 2005; Ebner and Chen, 2003),
although more conclusive data should be provided in this
regard.
The motor performance of some EA1 patients is altered
mostly during attacks when they display imbalance and
uncontrolled movements, mostly triggered by emotional and/or
physical stress. Kv1.1V408A/+ animals recapitulate the stress-
induced motor dysfunctions often observed in patients. Indeed,
pretreatment with low dose of isoproterenol, a β-adrenergic
agonist, significantly decreased the latency to fall and increased
the number of missteps of Kv1.1V408A/+ animals compared
to WT littermates (Herson et al., 2003). However, in the
resting condition or after exercise, the motor coordination of
Kv1.1V408A/+ mice were normal.
Hippocampus
The hippocampus of the limbic system is associated primarily
with memory consolidation, and in particular with spatial
memory. EA1 may be associated with cognitive symptoms
and seizures and therefore, abnormalities within hippocampal
circuitries have been suggested to play a role in this disease.
Kv1.1, Kv1.2 and Kv1.4 are abundantly expressed in Schaffer
collateral axons, as well as in the axons and terminals of the
medial perforant pathway of the dentate gyrus. CA3 mossy fibre
boutons that from en passant synapses with pyramidal neurons
express a channel complex composed of Kv1.1, 1.4 and Kvβ1.1
known to regulate the activity-dependent spike broadening and
glutamate release during high-frequency stimulation (Geiger
and Jonas, 2000). EA1 mutations drastically alter the function
of heteromeric channels composed of Kv1.1, Kv1.2, Kv1.4
and Kvβ1.1 subunits and may therefore, contribute to seizure
susceptibility and cognitive symptoms in EA1 (Imbrici et al.,
2006, 2011).
Kv1.1/Kv1.4/Kvβ1.1 channels possess high sensitivity to Zn2+
inhibition (see above). Although the effect of Zn2+ ions on
brain excitability remains controversial, there are evidence that
proof otherwise. For example, intracranial administration of
Zn2+ salts has been associated with epileptiform activity and
changes in Zn2+ modulation of GABA receptors have been
implicated in the etiology of epilepsy. In addition, granule
cell epileptiform activity is facilitated by the release of Zn2+
from recurrent mossy fibers (Timofeeva and Nadler, 2006).
Mossy fibre boutons contain Zn2+ stored at high concentrations
in pre-synaptic vesicles (approximately 300 µM; Frederickson,
1989). In the hippocampus, Zn2+ is released from mossy fiber
terminals during synaptic activity (Assaf and Chung, 1984)
into the synaptic cleft where they more than likely decrease
the activity of channels composed of Kv1.1/Kv1.4/Kvβ1.1
subunits. Imbrici et al. (2007) suggested that Zn2+ inhibition
of Kv1.1-containing channels, combined with the intrinsic
loss of channel function, caused by the KCNA1 mutations,
would exacerbate EA1 symptoms. These combined inhibitory
effects on K+ currents would impair the integration and
transmission of signals within distinct brain areas such as the
hippocampus and cerebellum (Imbrici et al., 2007). Intriguingly,
a distinct EA1 mutation (F184C) increased several folds the
intrinsic Zn2+ sensitivity of Kv1.1-containing channels and
epilepsy was reported in the patient carrying this mutation
(Browne et al., 1994; Cusimano et al., 2004). Investigations
aimed at establishing whether Zn2+ plays a role in cognitive,
epileptic and cerebellar EA1 symptoms are ongoing in our
laboratory. The neurophysiological role of Kv1.1 channels in
the hippocampus, and the relevant mechanisms underlying
seizure susceptibility has been investigated in animal models of
Kv1.1 channelopathies. We have recently reviewed the progress
in the neurobiology of ‘‘Kv1.1 channelepsy’’ in the following
publications: D’Adamo et al. (2013, 2014) that are available for
further insights.
Peripheral Nervous System
In the myelinated axons of the PNS it is possible to recognize
several specialized domains: the node of Ranvier, paranode,
juxtaparanode and internode. Kv1.1, Kv1.2 and the accessory
subunits Kvβ1.2 form a macromolecular complex in the
juxtaparanodal region and in axon branching points but is absent
at both the end-plate and muscle fibers (Tsaur et al., 1992;
Wang et al., 1993, 1994; Poliak et al., 1999; Vacher et al., 2008).
Neuromytonia and myokymia are present in the limbs and
particularly in the face and hands of EA1 patients. The EMG
of myokymic patients display patterns of either rhythmic or
arrhythmic singlets, duplets, or multiplets that may be apparent
after application of regional ischemia (e.g., using an inflated
sphygmomanometer cuff applied around the upper or lower
arm for up to 15 min). Patients manifesting neuromyotonia or
myokymia, and harboring different KCNA1mutations displayed
100% higher axonal hyperexcitability compared to healthy
controls (Tomlinson et al., 2010).
The neurophysiological role of Kv1.1 channels in
neuromuscular transmission has been elucidated by using
transgenic mouse models. These studies pointed out that
juxtaparanodal Kv1.1 channels are critical regulators of axonal
excitability. In fact, Kv1.1 ablation in mice causes repetitive
neuronal activity in the phrenic nerve resulting from both
spontaneous and stimulus-evoked nerve-backfiring at pre-
terminal axon transition zones. At these zones axons change
from myelinated to non-myelinated (Smart et al., 1998; Zhou
et al., 1998, 1999; Vabnick et al., 1999). This scenario is consistent
with computer simulations showing that lack of juxtaparanodal
Kv1.1 channels lead to reentrant excitation of nodes due to nerve
backfiring at axon transition zones of myelinated nerve terminals
(Zhou et al., 1999).
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Slower repolarization phases of the compound action
potentials and repetitive electrical activity was observed in the
phrenic nerve-muscle preparation of Kv1.1−/−mice (Smart et al.,
1998; Zhou et al., 1998, 1999; Vabnick et al., 1999). These
findings let us postulate that the respiratory symptoms reported
in some individuals with EA1 may also be caused by abnormal
transmission of signals along the phrenic nerve (Shook et al.,
2008). By using lateral gastrocnemius nerve–muscle preparations,
in vivo and in vitro, we observed that Kv1.1V408A/+ mice
displayed spontaneous myokymic—like discharges (repeated
singlets, duplets or multiplets) and abnormal Ca2+ signals
(Brunetti et al., 2012). Single nerve stimulation or stresses, such
as fatigue, lower temperatures and ischemia, exacerbated these
electrical abnormalities. Brunt and vanWeerden (1990) observed
an increase in spontaneous activity and burst frequency in EA1
individuals during the first fewminutes of limb ischemia induced
by an inflated sphygmomanometer. In some instances, after
5–10 min of ischemia the spontaneous discharges disappeared.
In contrast, recruitment of new and large multiplets and
enlargement of pre-existing complexes with extra spikes were
also observed following ischemia. This excess of activity began
0.5–1 min after reversal of ischemia, reached a maximum at
2–5 min and gradually declined over 10–15 min. Strikingly,
Kv1.1V408A/+ mice recapitulated faithfully also these EA1
neuromuscular findings (Brunetti et al., 2012). Cooling-induced
severe neuromyotonia and ataxia were also observed in a rat
model of EA1 (Ishida et al., 2012). The distinct expression
of Kv1.1 in axonal structures and the fact that spontaneous
discharges are present, in vivo, despite severing the motor
nerve supplying the Kv1.1V408A/+ muscle or, in in vitro
investigations, indicate that the sciatic nerve is an intrinsic site
of origin of anomalous re-excitation. This represents a more
clear indication that neuromyotonia/myokymic activity in EA1
patients originates also from hyper-excitability of the peripheral
nerve endings.
Ion Channel-Modulating Drugs in EA1
Therapy
Several drugs improve symptoms in patients with EA1 but so far,
with the lack of studies and trials comparing efficacy of these
drugs, no single medication has been proven effective.
Acetazolamide (ACTZ), a carbonic anhydrase inhibitor,
is used to reduce frequency and severity of EA1 attacks.
While some EA1 patients experience improvement with ACTZ,
responsiveness to ACTZ treatment is only occasional (Jen et al.,
2007). The mechanism by which ACTZ reduces symptoms
in responsive EA1 patients is unclear. Interestingly, stress-
induced motor dysfunctions in animals with a EA1 mutation
(Kv1.1V408A/+) are ameliorated by ACTZ, thus supporting its
therapeutic potential (Herson et al., 2003). ACTZ may act by
modulating intracellular pH or HCO3− gradient. It affects CSF
pH that may be responsible for its therapeutic effect, since
patients with ACTZ-responsive ataxia have regional alkalosis.
Normalization of intracellular pH after ACTZ treatment has been
observed in episodic ataxia type 2 (EA2) and cerebellar ataxic
patients (Bain et al., 1992; Sappey-Marinier et al., 1999). As a
consequence of pH adjustments, channels and ionic conductance
across neuronal membranes may be modulated, causing
membrane hyperpolarization and a decrease in excitability that
may manifest as the observed reduction in attacks. On the
other hand, ACTZ’s effect may be due to the development
of a HCO3− gradient that opposes the depolarizing Cl− shift
responsible for the inversion of the signal, from an inhibitory
to excitatory, mediated by the ligand-gated ion channel GABAA.
Alternatively, ACTZ may reduce excitability of GABAergic
interneurons as a consequence of intracellular alkalization
(Herson et al., 2003). However, ACTZ possess a potent ability to
open calcium-activated potassium channels (BK) and this action
was proposed as a possible therapeutic mechanism improving
myotonia (Tricarico et al., 2013). Unfortunately, the decrease
in efficacy of ACTZ over time (Zuberi et al., 1999) and the
development of adverse side effects (Lubbers et al., 1995) has
led to the discontinuation of ACTZ treatment in many of those
who are ACTZ-responsive. Long-term side effects of ACTZ
include nephrolithiasis, hyperhidrosis, paresthesias, rash, diffuse
weakness, and gastrointestinal discomfort (Kotagal, 2012). ACTZ
treatment should be avoided in individuals with liver, renal, or
adrenal insufficiency.
The antiepileptic drug, sulthiame is another carbonic
anhydrase inhibitor that reduces frequency of attacks. During
treatment with sulthiame, however, abortive attacks lasting a few
seconds were still noticed. Paresthesias and intermitted carpal
spasms were the troublesome side effects observed in patients
treated with this drug.
Phenytoin is a modulator of voltage-gated Na+ channels,
currently used as antiepileptic drug, that is also capable
of decreasing ataxia (VanDyke et al., 1975) and myokymia
(Gancher and Nutt, 1986) in EA1 patients. Phenytoin controlled
seizures by blocking sustained high frequency repetitive action
potentials (VanDyke et al., 1975). Moreover, it improved muscle
stiffness and motor performance (Kinali et al., 2004). In other
reported cases, however, phenytoin showed no effect (Brunt and
van Weerden, 1990; Zuberi et al., 1999). Despite its possible
therapeutic potential, phenytoin should be used with caution
particularly in young individuals, as it may cause permanent
cerebellar dysfunction and atrophy (De Marco et al., 2003).
Carbamazepine (CBZ) stabilizes the inactivated state of
voltage-gated Na+ channels, making fewer of these channels
available to subsequent opening. Also CBZ has been used
to ameliorate EA1 symptoms (Eunson et al., 2000). In an
animal model of temporal lobe epilepsy (Kv1.1S309T/+ rats), CBZ
administration ameliorated behavioral phenotypes and abnormal
discharges occurring in the cortex and hippocampus (Ishida
et al., 2012). CBZ significantly reduced the frequency of attacks
in members of a large Australian family (Hand et al., 2001).
Similarly, all 16 affected members of a large British family with
V404I mutation, who displayed typical EA1 attacks, responded
well to CBZ (Eunson et al., 2000). In some cases, however,
the CBZ initial response was not sustained (Zuberi et al., 1999;
Eunson et al., 2000).
Responses of EA1 patients to medication are variable, being
observable also amongst members of families harboring the
same KCNA1 mutation. Indeed Scheffer et al. (1998) reported
Frontiers in Cellular Neuroscience | www.frontiersin.org 6 August 2015 | Volume 9 | Article 317
D’Adamo et al. The neurobiology of episodic ataxia type 1
patients from a family harboring a V404I mutation who were
not responsive to treatment with ACTZ, while in another family
with the same mutation a 50% reduction in attacks after ACTZ
treatment was observed (Tacik et al., 2015).
Concluding Remarks
Fourty years ago, VanDyke et al. (1975) described EA1,
distinctively. Since then, a wealth of new findings, resulting
from genetics and electrophysiological investigations, clarified
the causes underlying this neurological disease, which emerges
as severe in some individuals. Concerning this last issue, it is still
unclear why patients, carrying even the same KCNA1 mutation,
exhibit very different disease phenotypes and severity. Elusive
epigenetic factors are often invoked to explain such remarkable
differences. Unclear are also the mechanisms determining the
episodic nature of EA1 and how physiological stresses, which
stimulate otherwise normal responses in healthy subjects, trigger
attacks of ataxic gait in patients. Finally, the lack of a highly
specific drug able, ideally, to enhance the activity of Kv1.1-
containing channels and offset the biochemical and biophysical
defects caused by the KCNA1 mutations, makes treatment of
EA1 problematic. The major challenges in the near future should
be aimed at finding answers to these and other puzzling issues
relevant to fully understand EA1.
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